$-0.77 EPS Expected for Tonix Pharmaceuticals Holding Corp. (TNXP)

July 14, 2018 - By Patrick Harkless

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Logo

Analysts expect Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) to report $-0.77 EPS on August, 13.They anticipate $0.12 EPS change or 18.46 % from last quarter’s $-0.65 EPS. After having $-0.88 EPS previously, Tonix Pharmaceuticals Holding Corp.’s analysts see -12.50 % EPS growth. The stock decreased 1.00% or $0.04 during the last trading session, reaching $3.95. About 144,657 shares traded or 10.85% up from the average. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has declined 28.97% since July 14, 2017 and is downtrending. It has underperformed by 41.54% the S&P500.

Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. The company has market cap of $33.42 million. The Company’s lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder , which is in Phase 3 study in the military-related PTSD population. It currently has negative earnings. The firm is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.

More recent Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) news were published by: Benzinga.com which released: “40 Biggest Movers From Friday” on June 18, 2018. Also Benzinga.com published the news titled: “28 Stocks Moving In Monday’s Mid-Day Session” on July 09, 2018. Benzinga.com‘s news article titled: “30 Biggest Movers From Yesterday” with publication date: July 10, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.